Skip to main content
Tech.euFundingExplorerBeta

Valo Therapeutics

Valo Therapeutics is an immunooncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines.

Valo Therapeutics has raised €33M across 4 funding rounds from 7 investors, most recently a round in Mar 2025. Based in Helsinki, Finland; founded 2016; active in Healthtech. Data as of 28 Oct 2026.

Helsinki, FinlandFounded 2016www.valotx.com ↗
Healthtech
← All companies
Total raised
€33M
€33,330,000
Funding rounds
4
Investors
7
distinct backers
Active since
2020-02
latest 2025-03

Funding by year

EUR raised per year
Valo Therapeutics — funding by year — interactive chart.
Data table
Valo Therapeutics — funding by year
2020€1.1M
2021€11M
2023€2.2M
2025€19M

Signals

High confidence
Raise-next likelihood42
base rate 30% for Other
  • ▲ In typical raise window
  • ▲ Up-round momentum
  • ▼ Low backer re-investment
Exit likelihood12
base rate 11% (2+ rounds)
  • ▲ €30M+ raised
  • ▲ 4 rounds raised
  • ▲ 10y since founding (typical exit age)
  • ▼ No recent equity round (debt-only or quiet)

Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

4 rounds
DateStageAmountInvestors
2025-03-10Other€19MCDP Venture Capital,ENEA Tech e Biomedical,Freeman Road,Indaco Venture PartnersView deal →
2023-02-15Other€2.2MEuropean Innovation CouncilView deal →
2021-11-15Pre-Seed€11MFreeman Road,MMJ Group HoldingsView deal →
2020-02-06Other€1.1MBusiness FinlandView deal →

Investors

7
Business FinlandCDP Venture CapitalENEA Tech e BiomedicalEuropean Innovation CouncilFreeman RoadIndaco Venture PartnersMMJ Group Holdings

Related news

Similar companies

same sector or country

Global coverage: FundingData